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Abstract 
The directive 2001/20/UE and the research involving patients with docs. Research 
involving patients with disorders of consciousness (DOCs) deserves special ethical and 
legal attention because of its Janus-faced nature. On the one hand, it raises concerns 
about the risk to expose the involved subjects to disproportionate risks not respecting 
their individual dignity, particularly their right to be cared for; on the other hand, re-
search is an essential tool in order to improve the clinical condition of patients with 
DOCs. The present paper concerns the ethical and legal dimensions of biomedical re-
search involving patients with disorders of consciousness. In particular, it focuses on 
informed consent to experimental treatments, which is a challenging issue both from an 
ethical and legal point of view. The first part reads the Directive 2001/20/EU in the light 
of the experimentation of patients with DOCs, and suggests a revision in order to better 
assess the issue of informed consent.
The particular case of informed consent for observational studies of non-communi-
cative patients. The second part presents an informed consent form for studies through 
video-recording of patients unable to communicate their own consent. This form has 
been elaborated by the bioethics unit of the project “Review of the nosography of veg-
etative states: application of methods of behavioral analysis to individuals in coma or 
vegetative state” developed at the Italian National Institute of Health.
Relevance of the suggested form. The paper describes the conceptual framework of 
the form for informed consent to studies through video-recoding, which is a relevant 
example of what issues should be included in an informed consent for any type of studies 
through video-recording of patients unable to express their own consent. The article has 
been sent on November the 7th 2013, before the adoption of the Regulation (EU) no. 
536/2014 (and consequent abrogation of the Directive 2001/20/EU) and the release of 
the new edition of the Italian Code of Medical Ethics.
INTRODUCTION
Because of the invasive nature of the required pro-
cedures (e.g., intra-arterial or jugular lines required for 
quantification of PET data or modeling), or the use of 
neuromuscular paralytics, ethical concerns have been 
raised on the involvement of patients with disorders of 
consciousness (DOCs) in research trials, such as func-
tional neuroimaging studies [1]. Other ethical and legal 
worries can be raised concerning the use of experimen-
tal pharmacological treatments on such patients. A pro-
visional list of concerns that arise from the involvement 
of patients with DOCs in research trials includes: 
- how to obtain knowledge which can be assumed as 
statistically significant and generalizable given the 
limited number of patients in such conditions;
- how to assess risks and benefits for such patients 
emerging from ordinary and research treatments;
- how to differentiate between risks and benefits 
emerging from ordinary therapeutic treatments, 
and risks and benefits emerging from research 
treatments;
- how to avoid the risk of misdiagnosis of minimally 
conscious (MCS) patients as vegetative state/un-
responsive wakefulness syndrome (VS/UWS) pa-
tients (diagnostic error);
- how to track the evolution of the health condition 
of patients with DOCs (prognostic error): long-
term residential facilities are often ill-equipped to 
track the evolution of the patient’s condition;
- how to integrate the healthcare system of patients 
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with DOCs, particularly enhancing the collabo-
ration between academic research centers and 
healthcare facilities, such as skilled nursing facili-
ties, acute rehabilitation centers, hospitals, clinical 
units, long-term residential facilities;
- how to enhance the communication between the 
research and the healthcare system components;
- how to manage the movement of patients among 
the different system components.
The fundamental ethical and legal concern regarding 
the involvement of patients with DOCs in research trials 
is the impossibility of such patients to express their per-
sonal informed consent. A reasonable approach to this 
issue may be to find an adequate equilibrium between 
access to research and medical advances, and the protec-
tion of patients that are particularly vulnerable [1].
On the one hand, research on patients with DOCs is 
an essential task of contemporary medicine in collabo-
ration with neuroscience. In fact, some studies have 
showed that there is insufficient evidence to recom-
mend one treatment instead of another in the clinical 
care of patients with DOCs [2, 3].
On the other hand, patients with DOCs deserve 
special attention and procedural protections. For in-
stance, the necessary precaution in the management of 
research on patients with DOCs must be informed with 
the risk that these “patients are also vulnerable to being 
denied potentially life-saving therapy if clinical research 
cannot be performed adequately” [1].
Some factors limiting the research on patients with 
DOCs have been described [4]:
- the centralization of scientific expertise in academ-
ic centers with the exclusion of short or long-term 
recovery facilities that host the largest number of 
patients of interest;
- the lack of or the difficulty to organize a method 
of surveillance in order to assess relevant variables 
of therapeutic and research protocols, such as inci-
dence, prevalence, treatment efficacy, cost of care 
or long-term functional outcomes;
- the excessive dispersion of the patient population 
making it difficult to detect potential subjects for 
research;
- the limited financial resources;
- the difficulties of non-academic centers to partici-
pate in research.
However, the main ethical problem concerning re-
search involving people with DOCs is the impossibil-
ity to obtain informed consent to participate in the re-
search activity. 
Another problematic condition is the direct ben-
efit for the enrolled subjects. Actually this condition 
is problematic not only for research on patients with 
DOCs, but for clinical research involving people unable 
to express their informed consent in general. According 
to the n. 28 of the latest version of the Helsinki Dec-
laration, such subjects can be involved in research only 
if three conditions are respected: there is likelihood of 
benefit for them or for the group represented; the re-
search cannot be performed with subjects able to pro-
vide an informed consent; the research entails no more 
than minimal risk and burden [5].
Other particular problems arise from the implemen-
tation of a randomized controlled trial (RCT) involving 
patients with DOCs:
- phase I, aimed at assessing safety, identifying col-
lateral effects, defining a safe dosage, understand-
ing how the agent is absorbed and eliminated by 
the body (pharmacokinetics/dynamics), is not easy 
to implement. It can be difficult to obtain signifi-
cant data from healthy volunteers or from patients 
with DOCs in an advanced stage of the disease: 
several aspects of DOCs are not comparable with 
healthy volunteers, and the condition is so critical 
that an advanced stage implies the death of the pa-
tients;
- phase II seems to not raise problems for patient 
with DOCs different than the problems arising 
from the involvement of other kinds of patients, 
particularly the assessment of risk;
- phases III and IV, involving hundreds to thousands 
or hundreds of thousands of patients, are challeng-
ing because of the relatively limited number of 
patients which risks to compromise the statistical 
relevance of the study;
- the confidentiality of the enrolled patients seems 
problematic because the limited number of pa-
tients hosted in each center risks making them eas-
ily identifiable;
- the management of control groups seems difficult, 
particularly for the use of placebo.
THE DIRECTIVE 2001/20/UE AND
THE RESEARCH INVOLVING PATIENTS
WITH DOCS
Article 3 of the Directive 2001/20/EU focuses on the 
“Protection of clinical trial subjects”.
In particular, regarding the specific case of patients 
unable to express their informed consent, article 3(1) 
delegates the member States to “adopt detailed rules 
to protect from abuse individuals who are incapable of 
giving their informed consent”.
Article 3(2) states the conditions a clinical trial must 
respect in order to be undertaken:
1. the foreseeable risks and inconveniences must be 
weighed against the anticipated benefit for the 
enrolled subject and other actual or potential sub-
jects. A balance between individual risks and indi-
vidual/public benefits is mandatory (art. 3(2)(a));
2. the trial subject or his legal representative must be 
informed and must have understood objectives, 
risks and inconveniences of the trial, the conditions 
for its conduction and his right to withdraw from 
the trial at any moment (art. 3(2)(b));
3. the right of the patient to physical and mental in-
tegrity, to privacy and to a confidential treatment 
of his data (art. 3(2) (c));
4. the trial subject or his legal representative must 
have given his written consent (or in exceptional 
cases his oral consent) after being informed of the 
nature, the significance, the implications and the 
risks of the trial (art. 3(2)(d));
5. the right of the subject to withdraw from the trial at 
any moment without any detriment;
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6. the insurance or indemnity to cover investigator’s 
and sponsor’s liability has been made.
These conditions can be read with particular refer-
ence to the treatment of patients with DOCs.
Regarding condition 1, according to Liddell and 
colleagues [6], it is an expression of an aggregate risk 
analysis: it starts from an identification of research 
with therapy without distinguishing therapeutic and 
research components of clinical experimentation. For 
this reason, according to the authors, the article 3(2)(a) 
offers little protection to incapacitated adults because 
it allows the risk of research to be offset by anticipated 
benefits of clinical care, so that it allows the benefit to 
the public to outweigh any degree of risk to the indi-
vidual. Clinical equipoise is not mentioned. 
Furthermore, in the case of patients with DOCs, par-
ticularly with permanent vegetative state (PVS), it is not 
clear how to define individual risks and benefits or how 
to balance them.
Conditions 2, 4 and 5 seem to be appropriate even 
for patients with DOCs, or better for their legal repre-
sentatives.
Condition 3 seems problematic for patients with 
DOCs. Besides the critical neurological condition af-
fecting the patient, mental integrity could be compro-
mised by the use of particular drugs (e.g., painkillers), 
which could decrease the level of awareness. Moreover, 
the relatively limited number of this type of patients 
and of the centers specialized in the research on them 
could affect the right to privacy of the trial patients. 
Condition 6 applies to research on patients with 
DOCs as well.
Article 5 of the Directive 2001/20/EU specifically fo-
cuses on “Clinical trials on incapacitated adults no able 
to give informed legal consent”.
As a general prerequisite, to be included in a clinical 
trial the patient must not have refused informed con-
sent before the onset of his incapacity. 
The following particular conditions must be respected:
1. the informed consent of the legal representative 
must have been obtained; this consent can be with-
drawn at any time without any detriment to the 
patient (art. 5(a));
2. the person not able to express her consent must have 
been informed about the trial, its risks and benefits 
according to her capacity to understand (art. 5(b));
3. the explicit wish of a subject able to form an opin-
ion and able to refuse to participate to the trial or 
able to withdraw from the trial at any time must be 
taken into account by the investigator (art. 5(c));
4. incentives or financial inducements, except com-
pensation, are forbidden (art. 5(d));
5. the research must be essential to validate data ob-
tained in clinical trials on persons able to give in-
formed consent or by other research methods, such 
as animal research, and the research must relate 
directly to a life-threatening or debilitating clinical 
condition affecting the involved subject (art. 5(e));
6. the trial must be designed in order to minimize 
pain, discomfort, fear and any other risk (art. 5(f));
7. the Ethics Committee must have endorsed the 
protocol (art. 5(g));
8. the interest of the individual must prevail over 
those of science and society (art. 5(h));
9. it is expected that administering the tested medici-
nal product will produce a benefit to the patients 
outweighing the risks or no risks at all (art. 5(i)).
These conditions are revised as follows by the article 
30 of the “Proposal for a regulation of the European 
Parliament and of the Council on Clinical Trials on Me-
dicinal Products for Human Use, and Repealing Direc-
tive 2001/20/EC”:
“(a) the informed consent of the legal representative 
has been obtained, whereby consent shall represent the 
subject’s presumed will;
(b) the incapacitated subject has received adequate 
information in relation to his or her capacity for under-
standing regarding the trial, the risks and the benefits;
(c) the explicit wish of an incapacitated subject who 
is capable of forming an opinion and assessing this in-
formation to refuse participation in, or to be withdrawn 
from, the clinical trial at any time is considered by the 
investigator;
(d) no incentives or financial inducements are given 
except compensation for participation in the clinical 
trial;
(e) such research is essential to validate data obtained 
in clinical trials on persons able to give informed con-
sent or by other research methods;
(f) such research relates directly to a life-threatening 
or debilitating medical condition from which the sub-
ject suffers;
(g) the clinical trial has been designed to minimise 
pain, discomfort, fear and any other foreseeable risk 
in relation to the disease and developmental stage and 
both the risk threshold and the degree of distress are 
specially defined and constantly observed;
(h) there are grounds for expecting that participation 
in the clinical trial will produce a benefit to the inca-
pacitated subject outweighing the risks or will produce 
no risk at all” [7].
Conditions 3 and 4, which correspond to the condi-
tions c and d respectively, seem to be appropriate for 
patient with DOCs as well.
Condition 7, which, as appropriately outlined [8, 9], 
has no correspondence in the Proposal, seems to be ap-
propriate for patient with DOCs as well.
Condition 1 corresponds to condition a, which adds 
that “consent shall represent the subject’s presumed 
will”. The cited Liddell et al. outline two problems aris-
ing from condition 1: no exceptions are recognized; no 
definition of legal representative are given. As a conse-
quence, different definitions of legal representative are 
elaborated in the different Member States. We agree 
about the second worry, while it is not clear what excep-
tions could or should be allowed.
Condition 2, which corresponds to condition (b), 
seems problematic: even if some recent experiments 
show the possibility to implement a sort of communica-
tion with patients with DOCs [10], it seems not realis-
tic to give them information about the trial: this is too 
complex to expect to be understood by the patient.
Condition 5, which corresponds to conditions 
(e)+(f), seems problematic, because given the com-
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plexity and the severity of the condition no data for 
validation could be available. Rather, this case seems 
to be perfectly in line with the requirements of the 
art. 28 of the Helsinki Declaration: “For a potential 
research subject who is incapable of giving informed 
consent, the physician must seek informed consent 
from the legally authorised representative. These indi-
viduals must not be included in a research study that 
has no likelihood of benefit for them unless it is in-
tended to promote the health of the group represented 
by the potential subject, the research cannot instead 
be performed with persons capable of providing in-
formed consent, and the research entails only minimal 
risk and minimal burden”.
Condition 6 corresponds to condition (g), which adds 
“in relation to the disease and developmental stage and 
both the risk threshold and the degree of distress are 
specially defined and constantly observed”. These con-
ditions seem problematic, because in case of patients 
with DOCs it is not scientifically clear if there are pain 
and suffering and how to assess them [11, 12].
Condition 8, which has no correspondence in the Pro-
posal, seems to be problematic if read in the light of a 
“component risk analysis” of research which distinguish-
es therapeutic and research components: while research 
is often (though not necessarily) combined with clinical 
care and other beneficial activities, it is the clinical ele-
ments that benefit the patient-participant [13, 14].
Condition 9, which corresponds to the condition 
(h), seems problematic. Liddell et al. outline that it is 
not clear how to apply the article 5(i) in case of clini-
cal equipoise. In fact the literal reading means that the 
researchers must expect that the test-drug is better than 
standard available treatment or it is risk free, but both 
these conditions are problematic if researchers observe 
(as they should) clinical equipoise.
The conclusion (emerging from the articles 3(2)(a) 
and 5(i)) is that the Directive has overlooked the clini-
cal equipoise, that is the genuine uncertainty by the 
medical community about the comparative therapeutic 
merits of each arm of a clinical trial. Yet for a researcher 
to not respect clinical equipoise means not to be in line 
with the Declaration of Helsinki and with the Addi-
tional Protocol to the Oviedo Convention [15], which 
is binding in many Member States.
Given the abovementioned problems, for instance 
Liddell et al. interpret the article 5(i) as follows: 
“There should be ground for expecting that adminis-
tering the medicinal product to be tested will produce 
a therapeutic benefit to the patient equivalent to standard 
treatment and outweighing the risks of therapy and pro-
duce no serious research risks at all” [6].
In other words, according to the authors an appro-
priate threshold is that research components entail no 
more than minimal risks. Such interpretation is in line 
with the Oviedo Convention [16], its Additional Pro-
tocol and the ICH-GCP guidance [17]. The National 
Bioethics Advisory Commission allowed more than 
minimal risk in some circumstances [18]. The Helsinki 
Declaration does not stipulate limits to the degree of 
risk, but that research must be justified by its potential 
value to future care. 
POINTS DESERVING MORE ATTENTION
IN RESEARCH INVOLVING PATIENTS
WITH DOCS
Research involving patients with DOCs raises several 
ethical and legal concerns. Such concerns require the 
revision of the Directive 2001/20/UE, particularly of 
the article 3 and 5 concerning “Protection of clinical tri-
al subjects” and “Clinical trials on incapacitated adults 
no able to give informed legal consent” respectively.
Such a revision should take into account the follow-
ing priority points:
- definition and management of (proxy) informed 
consent;
- definition of legal representative;
- assessment of therapeutic and research compo-
nents of experimentation involving patients with 
DOCs;
- enhancement of healthcare system for patients 
with DOCs;
- enhancement of research system for patients with 
DOCs;
- enhancement of the collaboration and integration 
between research and healthcare systems for pa-
tients with DOCs;
- enhancement of diagnostic and prognostic accu-
racy of healthcare and research involving patients 
with DOCs;
- definition and assessment of the statistical signifi-
cance of a study involving patients with DOCs;
- differentiation and assessment of risks and benefits 
for patients with DOCs;
- differentiation and assessment of individual and 
societal interests;
- definition of the involvement procedures for pa-
tients with DOCs in experimental study;
- definition of the involvement procedure for institu-
tions in research involving patients with DOCs;
- organization of a RCT involving patients with 
DOCs, particularly of phases I, III and IV, and the 
choice of control groups;
- assessment and respect of confidentiality of pa-
tients with DOCs involved in research procedures;
- definition and management of mental and physical 
integrity in case of patients with DOCs involved in 
research. 
THE PARTICULAR CASE OF INFORMED 
CONSENT FOR OBSERVATIONAL STUDIES 
OF NON-COMMUNICATIVE PATIENTS
In contemporary bioethics informed consent plays a 
central “inter-cultural” role as expression of the princi-
ple of autonomy, which stands as the fundamental right 
of patients [19]. Obtaining the informed consent, and 
consequently respecting autonomy, are particularly 
problematic issues in case of patients unable to com-
municate, such as patients with DOCs. The issues are 
particularly striking in the case of experimentation with 
such patients [20].
The problem is relevant both for ordinary and for ex-
perimental treatments, such as pharmacological, instru-
mental or observational studies, which imply a certain 
degree of uncertainty about the outcome of a treatment.
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We do not assume observational studies in their 
technical epidemiological and statistical mean-
ings, but more basically as the study of patients in 
VS/UWS or of other non-communicative patients 
through video-recording. 
Within the project “Review of the nosography of 
vegetative states: application of methods of behav-
ioral analysis to individuals in coma or vegetative 
state” developed by the Italian Istituto Superiore 
di Sanità (Italian National Institute of Health), the 
observational phase consists in monitoring patients 
with VS/UWS at the bedside and in video-recording 
their behavior with the aim to contribute to elabo-
rate a more detailed definition of DOCs. 
The project complies with the Italian Code for the 
Protection of Personal Data [21], of professional se-
crecy and of the Code of Medical Ethics (Chapter 
Four - Information and Consent, Articles 30 to 35).
Regarding video-recordings, it is specified that 
they are made in accordance with the recommenda-
tions and regulations on video acquisitions in health 
facilities [21, 22]. 
Since informed consent forms for such monitoring 
and recording seem not available in the literature, 
the bioethicists involved in the project elaborated a 
specific informed consent form. 
RELEVANCE OF THE SUGGESTED FORM
For all we know there is not a specific informed 
consent form for video-recording patients unable 
to communicate. Thus the proposed form could be 
internationally relevant for studies based on video-
recording of patients in VS/UWS or with other pa-
tients unable to express their own consent. In fact, 
several practical issues arise from video-recording 
patients unable to communicate, particularly from 
video-recording patients in VS/UWS [23]. These is-
sues, which must be assessed in the informed consent 
form, raise relevant ethical and legal implications.
Some national and international documents have 
assessed the general issue of video-recording patients. 
For instance, in 2002 the General Medical Council 
updated the guidance Making and using visual and 
audio recordings of patients [24]. In 2001 and 2003, 
the American Medical Association issued two opin-
ions about filming patients in healthcare settings 
[25] and for educational purposes [26] respectively. 
In Italy, the Italian Data Protection Authority issued 
a provision on “Video surveillance” in 2010 [27].
From the abovementioned sources it is possible to 
infer the following practical issues that an informed 
consent form for video-recording of non-communica-
tive patients, particularly of patients with VS/UWS, 
must clearly assess:
- Modality of video-recording: who does install the 
camera? Is an operator in the room for record-
ing? If yes, how long will he be present?
- Time of video-recording: is the recording 24 
hours? How long is the recording?
- Aim of video-recording: what type of research is 
the recording part of? What contribution could 
video-recording give to the quality of the record-
ed patients’ treatment? Could video-recording 
have direct clinical impact?
- Use of video-recording: for what is video-record-
ing used? For research only? Could it be used for 
dissemination, presentation, scientific communi-
cation, statistical analysis?
- Access to video-recording: who has access to the 
recorded videos? Only researchers who are part 
of the team or even other interested researchers? 
Are the family members allowed to watch the 
videos? How is the access to the videos managed 
in case the access to the ward is limited?
- Dissemination of video-recording: are the videos 
used in limited or public presentations? Can the 
collected data be used in scientific papers? If yes, 
are they previously anonymized? 
The ethical and legal questions arising from the
abovementioned practical issues are the following:
- confidentiality of patients’ personal data: the 
sensible information collected through recording 
must be protected and the access to it limited in 
order to respect the privacy of the patients;
- free participation to the study: no coercion 
should be applied to the patient’s family or legal 
representative to join the research;
- right to withdraw the consent: the legal repre-
sentative should retain the right to interrupt the 
patient’s participation to the study;
- quality of care: to participate or to not partici-
pate to the study cannot affect the quality of 
healthcare. No special rights will derive from the 
participation to the study, as well as no disadvan-
tages will derive from no participation.
In case of experimental studies with non-commu-
nicative patients, especially with patients with VS/
UWS, it is essential to assess the abovementioned 
issues. The proposed informed consent form is a rel-
evant example of how to clearly present these issues 
to patients’ families and/or to patients’ legal repre-
sentatives.
WHAT TO INCLUDE IN AN INFORMED 
CONSENT FORM FOR VIDEO-RECORDING 
PATIENTS UNABLE TO COMMUNICATE
We retain that in an informed consent form for video-
recording patients with VS/UWS the following points 
must be included as essential:
- a description of the project that requires the video-
recording, particularly of the project’s aims and its 
potential clinical implications;
- a description of the specific interventions the in-
formed consent regards, specifically modality and 
frequency of recording, number of copies that will 
be produced and their retention time, the use of 
recording for research and for scientific reporting, 
who have access to videos (e.g., researchers and not 
family if it is not allowed to visit the patient in the 
hospital department);
- laws regulating confidentiality;
- laws regulating video-recording;
- right of the person who signed the consent to re-
quire the videos at any time;
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- right of the person who signed the consent to with-
draw the consent at any time without any negative 
consequences on the clinical care of the patient;
- any other clinical parameter eventually measured 
during the registration;
- use of the data within the project and in the dis-
semination of its results;
- no use of the data in public projection.
In particular, studies through video-recording of 
patients with DOCs raise several critical and debated 
issues (e.g., autonomy, legal representation, surrogate 
informed consent, confidentiality, etc.). Besides the 
possible interpretation and assessment of these con-
troversial legal and ethical problems, the information 
described in the paper should be included in the in-
formed consent form for any study regarding this kind 
of patients in order to respect their rights.
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Appendix. 
Informed consent to video recording of patients in vegetative state
In recent years, different definitions of coma and persistent vegetative state have been elaborated, with particular regard to 
patients’ residual abilities. In general there is a broad consensus on the definition of severe disorders of consciousness, but 
the latest developments of scientific research and the new available technologies have allowed a more specific description of 
disorders of consciousness, allowing, for example, to distinguish between minimally conscious state, the so-called “permanent 
vegetative state” (that is reversible), the so-called “persistent vegetative state” (that is irreversible) and coma. For this reason, 
there is a need to elaborate a more detailed definition of such possible disorders. This is the aim of the research project of 
the Italian Institute of Health titled “Review of the nosography of vegetative states: application of methods of behavioral 
analysis to individuals in coma or vegetative state”. This project starts from the conviction that a more detailed description 
of the disorders of consciousness may be useful not only for a more accurate scientific knowledge, but also for a more ap-
propriate medical treatment. Anyway, any new treatment protocols do not fall directly in the project and will be eventually 
implemented only at a later stage, following the instructions of clinical practices, of professional ethics and, where relevant, 
of current legislation. A first step for achieving these aims is to monitor by video recording some patients in the so-called 
“vegetative” state in order to document all their spontaneous movements. Video recording will be done with a fixed camera, 
which does not require a full-time presence of an operator. After stabilization of post-trauma, patients will be recorded for a 
full day per week. After the first month, and for the next two months, patients will be recorded 24 hours a day on three alter-
nating days per week. In particular, both eye movements and motor responses, i.e. movements of the head or limbs, can be 
recorded. During the same period of video monitoring, audio recordings of auditory stimulation may also be used, in order to 
check the patients’ automatic reactions to short sentences of family members. In addition, the movements of the limbs will be 
measured by actigraphy, that is the use of automatic measuring of motion, which record the magnitude and duration of the 
movements. Several clinical parameters considered relevant to the study will be evaluated, particularly: heart rate, respiratory 
rate, electrocardiogram and some parameters obtainable from non-invasive neuroimaging techniques. The monitoring results 
are confidential and, therefore, like any other medical procedure in the strict sense, subject to the obligations and protections 
of existing law (Code for the Protection of Personal Data – so called Privacy Code, Legislative Decree no. 30/06 / 2003, 
No. 196), of professional secrecy and of the Code of Medical Ethics (Chapter Four - Information and Consent, Articles 30 
to 35). In particular, the video recordings will be made in accordance with the recommendations and regulations on video 
acquisitions in health facilities (Article 4.2 of the Order dated April 29, 2004 by the Ombudsman for Privacy Rights; Articles. 
22, paragraph 8, 83 and 167 of the so called Privacy Code, Legislative Decree no. 30/06/2003, n. 196). Moreover the recom-
mendations from authoritative institutions (such as, for example, the American Medical Association and the British General 
Medical Council) regarding video recording in a clinical setting will be respected. Thus the recordings will be made in compli-
ance with applicable law, we will produce … copies that will be kept for a period of months ... during which the person who 
signed the consent may revoke its decision to participate in the study and collect recordings.
(continues)
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I, the undersigned .........................................................................., born in ...................................... (Prov. .........)
on ..../..../........ (dd/mm/yyyy) and resident in ................................................................................... (Prov. ........) 
Postal Code ..................
Address...................................................................................................................n°......... tel................................
Holder of legal representation o
Relative not holding legal representation o
(tick as appropriate)
of the patient................................ admitted on ................................ at ................................
understood the information given to me by the staff, particularly about the aim of recording, its usefulness, the purpose of the 
study for which they take place and the possible implications of the results, DECLARE to be aware of:
- The way and the time of the video recordings
- The aims of the research and the possible use of recordings for scientific reporting
- The possibility to stop the recording in any time I believed appropriate, particularly if they had a somewhat negative influ-
ence on the professional conduct of health personnel
- The fact that no registration can be made other than that described in this form
- The fact that there will be no modification to the procedures described in this form
- The fact that the recordings will be made in order to not compromise the privacy and dignity of the patient
- The fact that the records will not be used for purposes other than those described in this form without further explicit 
consent
- The fact that it will be realized only the number of copies specified in this form, and they will be kept for the period speci-
fied in this form
- The fact that I may request the delivery of records at any time
- The fact that withdrawing from the agreement to make recordings or requiring the delivery of the records do not affect the 
quality of care in any way
- The fact that the records will be watched even by personnel not part of the unit of care, but part of the research project 
entitled “Review of the nosography of vegetative states: application of methods of behavioral analysis to individuals in coma 
or vegetative state”
- The fact that not even family members will be allowed to watch recordings when the department in which the patient is 
admitted does not allow their visit
- The fact that at the same time of video recording some clinical parameters deemed relevant will be measured
- The fact that the data emerging from records and surveys, after being suitably anonymised, will be used for the project “Re-
view of the nosography of vegetative states: application of methods of behavioral analysis to individuals in coma or vegetative 
state” and can therefore be included in publications, presentations, communications, scientific conferences, courses and any 
other method of dissemination will be considered appropriate
- The fact that the records will not be even partially projected in public spaces
I also declare to have had time and opportunity to ask questions and to have received satisfactory and understandable an-
swers. 
Therefore:
 I consent   I do not consent
The holder of handling personal data is the hospital…………………………………, 
located in …………………………………………, 
represented by the President, 
Tel. ……………......................…………, e-mail …………............................…………………. 
Place and date ............................................. Signed: ..........................................................
The doctor ............................................................................................................................  
Signed ...................................................................................................................................
To recording and monitoring clinical 
parameters of the following patient
...........................................................
(continued)
